Dissecting Cellulitis of the Scalp: From Etiology to Therapeutic Outcomes

Clinical Overview

Dissecting cellulitis of the scalp (DCS), also called perifolliculitis capitis abscedens et suffodiens, is a rare chronic suppurative scalp inflammation characterized by recurrent pustules, draining sinuses, bridging scars, and progressive alopecia. This condition is thought to be a response pattern of the scalp to chronic follicular inflammation rather than a true infectious cellulitis. DCS predominantly affects Black men (90% of cases) with onset typically in late teens to 30s, though the condition can affect any demographic. Without treatment, DCS progresses to extensive scarring alopecia, making early recognition and aggressive therapy critical.

Epidemiology

Dissecting cellulitis of the scalp is rare with estimated prevalence less than 0.01% in dermatology populations. However, prevalence is substantially higher in specific populations: affecting approximately 10-15% of men of African descent presenting with scarring alopecia, particularly in North America and Europe. The condition almost exclusively affects men (male-to-female ratio approximately 9:1), with peak onset in late teens to early 30s, though presentation into the 40s is possible. The pathogenesis is unclear; some researchers regard DCS as a severe form of folliculitis decalvans or a reactive response to chronic scalp folliculitis, while others consider it an independent disease entity. Familial clustering has been reported, suggesting possible genetic predisposition.

Pathophysiology

Dissecting cellulitis is characterized by chronic suppurative inflammation with active drainage and progressive scarring. Histologically, abscesses form around hair follicles, extend through dermis and subcutis, and create draining sinus tracts. The suppuration is often polymicrobial, though Staphylococcus aureus, Streptococcus species, and other bacteria are commonly cultured. Importantly, cultures do not reveal a single causative organism and treatment with antibiotics alone is often ineffective, suggesting the condition represents a host response pattern rather than true bacterial cellulitis. The progressive nature of DCS and poor response to antibiotics suggest autoimmune or inflammatory dysfunction. Some researchers hypothesize that abnormal sebaceous gland function, bacterial lipase production, or follicular obstruction initiates chronic inflammation that subsequently involves deep scalp structures.

Clinical Presentation

Dissecting cellulitis typically presents with recurrent pustules, abscesses, and draining sinuses on the scalp, often concentrated on the vertex and occipital regions. Patients report painful scalp swelling, purulent drainage, crusting, and progressive hair loss. The scalp appearance evolves from pustules and abscesses to extensive scarring with characteristic "bridging scars"—fibrotic strands connecting areas of alopecia and creating a pitted, deformed scalp surface. The condition is progressive and may extend over years, destroying progressively larger areas of scalp. Some patients develop systemic manifestations including fever and malaise during acute flares. The pain and drainage substantially impact quality of life and self-image, creating significant psychosocial burden. Unlike simple folliculitis, DCS shows persistent suppuration despite antibiotic therapy, leading to diagnostic confusion and treatment delays.

Diagnosis

Diagnosis is primarily clinical based on presentation of recurrent pustules, abscesses, and bridging scars on the scalp, particularly in a Black man in the appropriate age group. Bacterial culture from drain exudate typically grows multiple bacteria (Staphylococcus aureus plus other species), though no single organism is consistently isolated. Scalp biopsy reveals suppurative inflammation with abscess formation, follicular destruction, and prominent fibrosis. The findings may resemble folliculitis decalvans (severe neutrophilic folliculitis) or kerion from severe tinea capitis (fungal infection with host response). Imaging (ultrasound, MRI) may reveal abscess cavities and sinus tracts. Importantly, the presence of multiple organisms and poor response to antibiotics targeting individual pathogens support the diagnosis of DCS as an inflammatory response pattern rather than simple infection.

Treatment Algorithm

Treatment of DCS is challenging and requires combination of antimicrobial and anti-inflammatory agents. Monotherapy with antibiotics alone is typically insufficient; combined anti-inflammatory therapy is essential for disease control.

Antimicrobial therapy includes broad-spectrum oral antibiotics targeting common pathogens. Amoxicillin-clavulanate (875-125 mg twice daily) or cephalexin (500 mg four times daily) treat Staphylococcus and Streptococcus. For resistant organisms, clindamycin (300-450 mg 3-4 times daily) provides coverage. Given the polymicrobial nature and poor monotherapy response, some clinicians use dual antibiotic therapy (e.g., amoxicillin-clavulanate plus a macrolide). Courses are typically 4-8 weeks minimum, though prolonged treatment (months to years) is often necessary. Topical antibiotics (mupirocin to affected areas) and antiseptics (chlorhexidine washes) provide adjunctive benefit.

Anti-inflammatory therapy is critical and often more important than antimicrobials. Intralesional corticosteroid injection (triamcinolone 2.5-10 mg/mL) into actively draining areas every 4-6 weeks suppresses suppuration in 40-50% of patients. Oral corticosteroids (prednisone 0.5-1 mg/kg daily with gradual taper over 6-8 weeks) achieve response in approximately 50-60% of patients, though taper often results in flares, necessitating maintenance therapy.

Systemic anti-inflammatory agents are often needed. Oral retinoids (isotretinoin 0.5-1 mg/kg daily or acitretin at similar doses) show response in 50-60% of DCS patients. Cyclosporine (3-5 mg/kg daily) achieves response in 40-50% of refractory cases with monitoring of renal function. Mycophenolate mofetil (500-1000 mg twice daily) has shown promise in small series. Some dermatologists consider acitretin or cyclosporine first-line agents for systemic therapy in DCS.

Surgical intervention may be necessary for management of large abscesses or sinus tracts causing persistent drainage. Incision and drainage, sinus tract excision, or laser ablation of sinus tracts may reduce ongoing suppuration, though recurrence is common. Surgical approaches are typically combined with medical therapy rather than monotherapy.

Prognosis

Without treatment, DCS is progressive, causing extensive scarring alopecia and baldness of large scalp regions over years. With appropriate antimicrobial and anti-inflammatory therapy, approximately 50-60% of patients achieve disease stabilization or improvement. Complete disease control is less common; most patients require ongoing therapy. Early intervention with appropriate combination treatment optimizes outcomes. Late-stage disease with extensive scarring is often treatment-resistant. Scarring alopecia from DCS is permanent and irreversible; hair transplantation is generally not effective in actively progressive disease but may be considered after sustained disease stability for 12+ months.

When to See a Dermatologist

Men with recurrent scalp pustules, abscesses, and progressive hair loss require urgent dermatology evaluation for possible DCS. Early diagnosis and initiation of combined antimicrobial and anti-inflammatory therapy optimizes outcomes. Bacterial culture should be obtained to guide initial antibiotic selection, though responsiveness to antibiotics alone should prompt consideration of systemic anti-inflammatory therapy.

Frequently Asked Questions

Is dissecting cellulitis contagious? No. Despite suppuration and drainage, DCS is not contagious. Close contacts will not acquire the condition. The underlying pathology appears to be inflammatory rather than infectious.

Will antibiotics cure dissecting cellulitis? Antibiotics alone rarely cure DCS; the condition typically requires combination antimicrobial and anti-inflammatory therapy. Monotherapy with antibiotics often fails, supporting the hypothesis that DCS is fundamentally inflammatory rather than infectious.

Can my hair regrow after dissecting cellulitis? Follicles destroyed by suppuration and scarring cannot regenerate. Early treatment may prevent further hair loss; however, regrowth of permanently scarred areas is not possible through medical therapy.

How long will I need treatment? Most patients require months to years of continuous therapy to control DCS. Some achieve remission and discontinue medications; others require indefinite maintenance therapy to prevent recurrence.

References